证券代码：601607 证券简称：上海医药 编号：临 2026-020 上海医药集团股份有限公司 注册分类：化学药品 3 类 药品批准文号：国药准字 H20263655 申请人：上海禾丰制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 关于二羟丙茶碱注射液获得批准生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海禾丰制药 有限公司（以下简称"上药禾丰"）的二羟丙茶碱注射液（以下简称"该药品"） 收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品注册证书》 （证书编号：2026S00781），该药品获得批准生产。 一、该药品基本情况 药品名称：二羟丙茶碱注射液 剂型：注射剂 规格：2ml：0.3g 三、对上市公司影响及风险提示 根据国家相关政策，按新注册分类获批仿制药的品种在医保支付及医疗机构 采购等领域将获得更大的支持力度。因此上药禾丰的二羟丙茶碱注射液获得批 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), has received a Drug Registration Certificate from the National Medical Products Administration for its Dihydrocodeine Injection, which has been approved for production [1] Group 1 - The Dihydrocodeine Injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The medication can also be used for alleviating symptoms caused by pulmonary edema due to heart failure [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for its Dihydroxypropyl Theophylline Injection, which is approved for production [1] Group 1: Product Approval - The drug is classified as a Class 3 chemical drug and is indicated for the relief of symptoms in bronchial asthma and asthmatic bronchitis [1] - As of the announcement date, the company has invested approximately 3.14 million yuan in research and development for this product [1] Group 2: Market Potential - According to IQVIA data, the projected hospital procurement amount for this drug type in mainland China is 325 million yuan by 2025 [1] - The company believes that the approval of this product will enhance its market competitiveness and provide experience for future generic drug applications [1] Group 3: Risks - The company acknowledges that there are risks related to sales not meeting expectations due to policy and market factors [1]

Core Viewpoint - The company emphasizes long-term value management as a key strategy, focusing on market communication and shareholder returns while pursuing steady operational growth and diversified value management tools [1] Group 1: Value Management Strategy - The company is committed to enhancing market communication and shareholder returns as part of its long-term strategy [1] - The company aims to solidify its intrinsic value through steady growth in operational performance [1] - The controlling shareholder has announced a buyback plan to support the company's market value [1] Group 2: Dividend Policy - The company plans to maintain dividends at no less than 30% of the average distributable profits over the past three years for the next three years [1] - In 2024 and 2025, the company will increase the frequency of dividend payments, with future ratios to be determined based on actual operational conditions and cash needs [1] Group 3: Research and Development - The company has received approval for its self-developed drug, Succinic Acid Simoquin (Xintuoan), which is set to be launched by the end of December 2025, with the first prescription expected in February 2026 [1]

Group 1 - The public announcement period is set from March 20, 2026, to March 29, 2026 [2]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) will hold a board meeting on March 30, 2026, to approve the annual performance for the year ending December 31, 2025, and consider the distribution of a final dividend, if any [1] Group 1 - The board meeting is scheduled for March 30, 2026 [1] - The meeting will focus on approving the annual results for the fiscal year ending December 31, 2025 [1] - The board will also consider the potential distribution of a final dividend [1]

Shanghai Pharmaceuticals Holding Co., Ltd.* 02607 * ...

Group 1 - The company Shanghai Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for its injectable Cefazolin Sodium, indicating that the drug has passed the consistency evaluation for quality and efficacy of generic drugs [1][2] - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory, urinary, skin, soft tissue, bone, joint infections, sepsis, infective endocarditis, hepatobiliary infections, reproductive system infections, and for perioperative infection prevention [3] - The company has invested approximately RMB 3.3241 million in the research and development of this drug's consistency evaluation as of the date of the announcement [3] Group 2 - According to the IQVIA database, the procurement amount for injectable Cefazolin Sodium in hospitals in mainland China is projected to be RMB 1,107.58 million in 2025 [4] - The approval of the drug through the consistency evaluation is expected to enhance its market share and competitiveness, while also providing valuable experience for the company in conducting future consistency evaluations for other products [5]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shenyang New Asia Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium has been granted a supplementary application approval by the National Medical Products Administration [1] - The approval notice includes notification numbers 2026B01286 and 2026B01287 [1] - The drug has successfully passed the consistency evaluation of quality and efficacy, indicating its compliance with regulatory standards for generic medications [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Shenyang New Asia Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of perioperative infections [1]